J M Schattenberg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4418448/publications.pdf

Version: 2024-02-01

181 papers	12,902 citations	31902 53 h-index	28224 105 g-index
215 all docs	215 docs citations	215 times ranked	12269 citing authors

#	Article	IF	Citations
1	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 2020, 73, 202-209.	1.8	2,171
2	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016â€“2030. Journal of Hepatology, 2018, 69, 896-904.	1.8	1,157
3	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 2021, 592, 450-456.	13.7	649
4	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology, 2020, 158, 1611-1625.e12.	0.6	575
5	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. American Journal of Gastroenterology, 2017, 112, 740-751.	0.2	524
6	Jnk1 but not jnk2 promotes the development of steatohepatitis in mice. Hepatology, 2006, 43, 163-172.	3.6	348
7	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	8.2	330
8	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. New England Journal of Medicine, 2021, 385, 1547-1558.	13.9	284
9	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohortâ˜†. Journal of Hepatology, 2020, 73, 505-515.	1.8	279
10	Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis. Hepatology, 2019, 69, 2241-2257.	3.6	227
11	Nonâ€alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 68-76.	1.4	212
12	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Science Translational Medicine, 2020, 12, .	5.8	205
13	Liver injury in COVIDâ€19: The current evidence. United European Gastroenterology Journal, 2020, 8, 509-519.	1.6	182
14	Hepatocyte CYP2E1 Overexpression and Steatohepatitis Lead to Impaired Hepatic Insulin Signaling. Journal of Biological Chemistry, 2005, 280, 9887-9894.	1.6	174
15	GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2020, 18, 728-735.e4.	2.4	167
16	A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. Journal of Hepatology, 2020, 72, 816-827.	1.8	165
17	Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut, 2022, 71, 156-162.	6.1	162
18	Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. Journal of Lipid Research, 2017, 58, 247-255.	2.0	159

#	Article	IF	Citations
19	Animal Models of Non-Alcoholic Steatohepatitis: Of Mice and Man. Digestive Diseases, 2010, 28, 247-254.	0.8	125
20	Metabolic Inflammationâ€"A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?. Gastroenterology, 2020, 158, 1929-1947.e6.	0.6	120
21	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology, 2022, 75, 219-228.	3.6	107
22	Apoptosis in liver disease. Liver International, 2006, 26, 904-911.	1.9	106
23	Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation. Journal of Hepatology, 2018, 68, 986-995.	1.8	106
24	Administrative Coding in Electronic Health Care Recordâ€Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology, 2021, 74, 474-482.	3.6	102
25	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut, 2019, 68, 1099-1107.	6.1	100
26	Nonalcoholic steatohepatitis. Current Opinion in Lipidology, 2011, 22, 479-488.	1.2	98
27	Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut, 2016, 65, 1564-1571.	6.1	96
28	Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer, 2012, 12, 109.	1.1	94
29	NAFLD â€" sounding the alarm on a silent epidemic. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 377-379.	8.2	94
30	Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 213-219.	1.4	92
31	Predictors of advanced fibrosis in nonâ€cirrhotic nonâ€alcoholic fatty liver disease in Germany. Alimentary Pharmacology and Therapeutics, 2018, 48, 1109-1116.	1.9	88
32	Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer, 2015, 15, 210.	1.1	87
33	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Reports, 2019, 1, 188-198.	2.6	86
34	Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. Diabetologia, 2017, 60, 1873-1882.	2.9	85
35	Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Clinical Gastroenterology and Hepatology, 2019, 17, 2085-2092.e1.	2.4	79
36	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. Journal of Hepatology, 2021, 74, 1344-1354.	1.8	77

#	Article	IF	Citations
37	Disease burden and economic impact of diagnosed nonâ€alcoholic steatohepatitis in five European countries in 2018: A costâ€ofâ€illness analysis. Liver International, 2021, 41, 1227-1242.	1.9	76
38	Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients. Alimentary Pharmacology and Therapeutics, 2018, 48, 313-321.	1.9	73
39	Hepatocyte Resistance to Oxidative Stress Is Dependent on Protein Kinase C-mediated Down-regulation of c-Jun/AP-1. Journal of Biological Chemistry, 2004, 279, 31089-31097.	1.6	72
40	Defining comprehensive models of care for NAFLD. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 717-729.	8.2	72
41	Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression. Hepatology Communications, 2020, 4, 1293-1301.	2.0	70
42	Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. Journal of Hepatology, 2020, 73, 680-693.	1.8	69
43	Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat. Hepatology, 2005, 42, 1072-1081.	3.6	68
44	Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. Digestive Diseases and Sciences, 2020, 65, 2112-2119.	1.1	68
45	Improvement of nonâ€invasive markers of NAFLD from an individualised, webâ€based exercise program. Alimentary Pharmacology and Therapeutics, 2019, 50, 930-939.	1.9	67
46	CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. Hepatology, 2004, 39, 444-455.	3.6	65
47	Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncology Reports, 2006, 15, 227-30.	1.2	63
48	Regulation of the effects of CYP2E1-induced oxidative stress by JNK signaling. Redox Biology, 2014, 3, 7-15.	3.9	59
49	Chronic oxidative stress sensitizes hepatocytes to death from 4-hydroxynonenal by JNK/c-Jun overactivation. American Journal of Physiology - Renal Physiology, 2009, 297, G907-G917.	1.6	58
50	Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. Transplant International, 2013, 26, 67-74.	0.8	58
51	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 781-793.	3.7	58
52	Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo. Journal of Hepatology, 2011, 55, 1272-1280.	1.8	57
53	Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. Open Forum Infectious Diseases, 2016, 3, ofw011.	0.4	54
54	Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. Journal of Clinical Virology, 2012, 54, 93-95.	1.6	53

#	Article	IF	Citations
55	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. JHEP Reports, 2020, 2, 100142.	2.6	53
56	The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. Expert Opinion on Investigational Drugs, 2020, 29, 1365-1375.	1.9	46
57	Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. Digestive and Liver Disease, 2016, 48, 291-297.	0.4	44
58	Nonâ€alcoholic fatty liver disease increases the risk of incident chronic kidney disease. United European Gastroenterology Journal, 2020, 8, 942-948.	1.6	43
59	NAFLD in the Elderly. Clinical Interventions in Aging, 2021, Volume 16, 1633-1649.	1.3	43
60	Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. International Journal of Oncology, 2013, 42, 1297-1304.	1.4	42
61	Diabetes and apoptosis: liver. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 1459-1471.	2.2	38
62	Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. BMC Cancer, 2016, 16, 94.	1.1	37
63	Diabetic liver injury from streptozotocin is regulated through the caspase-8 homolog cFLIP involving activation of JNK2 and intrahepatic immunocompetent cells. Cell Death and Disease, 2013, 4, e712-e712.	2.7	35
64	Health-related quality of life in patients with compensated and decompensated liver cirrhosis. European Journal of Internal Medicine, 2019, 70, 54-59.	1.0	35
65	Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients, 2020, 12, 699.	1.7	33
66	Incident Dementia in Elderly Patients with Nonalcoholic Fatty Liver Disease in Germany. Digestive Diseases and Sciences, 2021, 66, 3179-3185.	1.1	32
67	Clinical Frailty Scale for Risk Stratification in Patients with Sars-Cov-2 Infection. Journal of Investigative Medicine, 2020, 68, 1199-1202.	0.7	32
68	Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters â€“ an animal model of life style intervention in NAFLD. Scientific Reports, 2019, 9, 4007.	1.6	31
69	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Reports, 2022, 4, 100477.	2.6	31
70	Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome. European Journal of Internal Medicine, 2011, 22, 305-310.	1.0	29
71	Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. American Journal of Physiology - Renal Physiology, 2012, 303, G498-G506.	1.6	29
72	Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers. Journal of Human Genetics, 2018, 63, 621-626.	1.1	29

#	Article	IF	Citations
73	Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2020, 52, 527-536.	1.9	29
74	Raised serum Interleukinâ€6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy. Alimentary Pharmacology and Therapeutics, 2019, 50, 1112-1119.	1.9	28
75	Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1235-1241.	2.2	28
76	Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis. American Journal of Gastroenterology, 2019, 114, 764-770.	0.2	27
77	Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Lowâ€Density Lipoprotein Cholesterol. Hepatology Communications, 2019, 3, 1472-1481.	2.0	26
78	The Patient Perspectives on Future Therapeutic Options in NASH and Patient Needs. Frontiers in Medicine, 2019, 6, 61.	1.2	26
79	Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD). European Journal of Internal Medicine, 2010, 21, 208-215.	1.0	25
80	Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy. European Journal of Internal Medicine, 2019, 60, 96-100.	1.0	24
81	Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis. Gastroenterology, 2019, 156, 692-707.e7.	0.6	24
82	Prevalence and Risk Factors of Advanced Liver Fibrosis in a Populationâ€Based Study in Germany. Hepatology Communications, 2022, 6, 1457-1466.	2.0	24
83	Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function. International Journal of Cardiology, 2018, 271, 296-300.	0.8	23
84	Patterns of liver injury in COVIDâ€19 â€“ a German case series. United European Gastroenterology Journal, 2020, 8, 814-819.	1.6	23
85	Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study. Journal of Medical Internet Research, 2019, 21, e11250.	2.1	23
86	Elevated levels of Bcl-3 inhibits Treg development and function resulting in spontaneous colitis. Nature Communications, 2017, 8, 15069.	5.8	22
87	Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver disease. Scientific Reports, 2019, 9, 17463.	1.6	21
88	The Impact of Liver Cell Injury on Health-Related Quality of Life in Patients with Chronic Liver Disease. PLoS ONE, 2016, 11, e0151200.	1.1	21
89	Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease. Deutsches Ärzteblatt International, 2020, 117, 719-724.	0.6	21
90	Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines, 2021, 9, 1920.	1.4	21

#	Article	IF	Citations
91	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. JHEP Reports, 2022, 4, 100409.	2.6	20
92	Risk Factors in Patients With Rapid Recurrent Hepatitis C Virusâ€"Related Cirrhosis Within 1 Year After Liver Transplantation. Transplantation Proceedings, 2009, 41, 2549-2556.	0.3	19
93	Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center â€œreal-lifeâ€•cohort. BMC Gastroenterology, 2015, 15, 97.	0.8	19
94	A novel device for intracolonoscopy cleansing of inadequately prepared colonoscopy patients: a feasibility study. Endoscopy, 2019, 51, 85-92.	1.0	19
95	The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care. JHEP Reports, 2020, 2, 100168.	2.6	18
96	Determining a healthy reference range and factors potentially influencing PRO-C3 â€" A biomarker of liver fibrosis. JHEP Reports, 2021, 3, 100317.	2.6	18
97	Extracellular Vesicles as Messengers Between Hepatocytes and Macrophages in Nonalcoholic Steatohepatitis. Gastroenterology, 2016, 150, 815-818.	0.6	17
98	Epidemiology of hepatic encephalopathy in german hospitals â€" the EpHE study. Zeitschrift Fur Gastroenterologie, 2017, 55, 741-747.	0.2	17
99	Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy. Journal of Clinical Gastroenterology, 2019, 53, e303-e307.	1.1	17
100	Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches. Nutrients, 2021, 13, 1977.	1.7	17
101	Applicability of a Web-Based, Individualized Exercise Intervention in Patients With Liver Disease, Cystic Fibrosis, Esophageal Cancer, and Psychiatric Disorders: Process Evaluation of 4 Ongoing Clinical Trials. JMIR Research Protocols, 2018, 7, e106.	0.5	17
102	The role of death effector domain-containing proteins in acute oxidative cell injury in hepatocytes. Free Radical Biology and Medicine, 2012, 52, 1911-1917.	1.3	16
103	Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors. Journal of Hepatology, 2016, 65, 1188-1197.	1.8	16
104	Loss of cellular FLICE-inhibitory protein promotes acute cholestatic liver injury and inflammation from bile duct ligation. American Journal of Physiology - Renal Physiology, 2018, 314, G319-G333.	1.6	16
105	Profiling and targeting connective tissue remodeling in autoimmunity - A novel paradigm for diagnosing and treating chronic diseases. Autoimmunity Reviews, 2021, 20, 102706.	2.5	16
106	The gut microbiota instructs the hepatic endothelial cell transcriptome. IScience, 2021, 24, 103092.	1.9	16
107	Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis. Oncotarget, 2017, 8, 115667-115680.	0.8	16
108	Symptom Burden and Treatment Response in Patients with Primary Biliary Cholangitis (PBC). Digestive Diseases and Sciences, 2020, 65, 3006-3013.	1.1	14

#	Article	IF	Citations
109	Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) â€“ how are clinical trials affected?. Expert Opinion on Investigational Drugs, 2020, 29, 93-97.	1.9	14
110	Risk factors for poorer health literacy in patients with liver cirrhosis. PLoS ONE, 2021, 16, e0255349.	1.1	14
111	Voluntary distance running prevents TNF-mediated liver injury in mice through alterations of the intrahepatic immune milieu. Cell Death and Disease, 2017, 8, e2893-e2893.	2.7	13
112	Resistanceâ€associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. Journal of Viral Hepatitis, 2020, 27, 974-986.	1.0	12
113	Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?. Hepatology Communications, 2020, 4, 141-144.	2.0	12
114	Hepatic sarcoidosis: Clinical characteristics and outcome. JHEP Reports, 2021, 3, 100360.	2.6	12
115	Acute organ failure following the loss of anti-apoptotic cellular FLICE-inhibitory protein involves activation of innate immune receptors. Cell Death and Differentiation, 2015, 22, 826-837.	5.0	11
116	New onset of diabetes after transplantation is associated with improved patient survival after liver transplantation due to confounding factor. European Journal of Internal Medicine, 2015, 26, 439-444.	1.0	11
117	Evaluation of ILâ€6 for Stepwise Diagnosis of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis. Hepatology Communications, 2022, 6, 1113-1122.	2.0	11
118	A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Alimentary Pharmacology and Therapeutics, 2022, 55, 234-243.	1.9	11
119	Leptomeningeal familial amyloidosis:. Journal of Neurology, 2006, 253, 1238-1240.	1.8	10
120	Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!. Journal of Cancer Research and Clinical Oncology, 2015, 141, 515-522.	1.2	10
121	The Snoring Index Identifies Risk of Non-Alcoholic Fatty Liver Disease in Patients with Obstructive Sleep Apnea Syndrome. Biology, 2022, 11, 10.	1.3	10
122	Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents. Digestive and Liver Disease, 2014, 46, 67-71.	0.4	9
123	On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis. Journal of Hepatology, 2020, 73, 1592-1593.	1.8	9
124	Impact of thyroid disorders on the incidence of nonâ€alcoholic fatty liver disease in Germany. United European Gastroenterology Journal, 2021, 9, 829-836.	1.6	9
125	Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1253-1266.	1.4	9
126	Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF-ÎºB activation. Oncotarget, 2017, 8, 56095-56109.	0.8	9

#	Article	IF	Citations
127	Effect of hepatic steatosis and associated metabolic comorbidities on healthâ€related quality of life in people living with HIV. Hepatology Communications, 2022, 6, 2011-2021.	2.0	9
128	Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients, 2019, 11, 588.	1.7	8
129	Nonalcoholic Fatty Liver Disease in 2020. Gastroenterology, 2020, 158, 1849-1850.	0.6	8
130	Referral care paths for nonâ€alcoholic fatty liver diseaseâ€”Gearing up for an ever more prevalent and severe liver disease. United European Gastroenterology Journal, 2021, 9, 903-909.	1.6	8
131	Transforming Growth Factor-Î² Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome. Cancers, 2022, 14, 430.	1.7	8
132	Validation of EncephalApp_Stroop as screening tool for the detection of minimal hepatic encephalopathy in German patients with liver cirrhosis. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101873.	0.7	8
133	Disclosure behaviour and experienced reactions in patients with HIV versus chronic viral hepatitis or diabetes mellitus in Germany. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2013, 25, 1259-1270.	0.6	7
134	The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm. Hepatology, 2017, 66, 666-667.	3.6	7
135	Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. Journal of Hepatology, 2017, 66, S593.	1.8	7
136	Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Digestive Diseases, 2018, 36, 78-88.	0.8	7
137	Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a populationâ€based study. Alimentary Pharmacology and Therapeutics, 2020, 52, 1042-1050.	1.9	7
138	Impact of acute-on-chronic liver failure and decompensated liver cirrhosis on psychosocial burden and quality of life of patients and their close relatives. Health and Quality of Life Outcomes, 2020, 18, 10.	1.0	7
139	An international survey on patterns of practice in NAFLD and expectations for therapiesâ€”The POPâ€NEXT project. Hepatology, 2022, 76, 1766-1777.	3.6	7
140	Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC. European Journal of Internal Medicine, 2018, 55, 57-65.	1.0	6
141	Response: Frailty assessment in the COVID-19 pandemic. Journal of Investigative Medicine, 2020, 68, 1302-1302.	0.7	6
142	Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. Expert Review of Molecular Diagnostics, 2021, 21, 1065-1078.	1.5	6
143	Treatment of Malignant Ascites with a Second Cycle of Catumaxomab in Gastric Signet Cell Carcinoma - a Report of 2 Cases. Oncology Research and Treatment, 2014, 37, 674-677.	0.8	5
144	Reading the stars for hepatic fibrosis or how to predict the severity of liver disease in patients with NASH. Liver International, 2019, 39, 812-814.	1.9	5

#	Article	IF	Citations
145	Refining Noninvasive Diagnostics In Nonalcoholic Fatty Liver Disease: Closing the Gap to Detect Advanced Fibrosis. Hepatology, 2019, 69, 934-936.	3.6	5
146	A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma. Zeitschrift Fur Gastroenterologie, 2020, 58, 57-62.	0.2	5
147	NAFLD between genes and environment: what drives fibrogenesis?. Gut, 2021, 70, 815-816.	6.1	5
148	Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care. PLoS ONE, 2021, 16, e0249342.	1.1	5
149	Health-related quality of life in patients with autoimmune hepatitis. Quality of Life Research, 2021, 30, 2853-2861.	1.5	5
150	Multidisciplinary approach to the complex treatment for non-cirrhotic portal hypertension â€“ case-report-based discussion. Zeitschrift Fur Gastroenterologie, 2021, 59, 43-49.	0.2	5
151	Liver Frailty Index for Prediction of Short-Term Rehospitalization in Patients with Liver Cirrhosis. Diagnostics, 2022, 12, 1069.	1.3	5
152	Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection. BMC Gastroenterology, 2017, 17, 26.	0.8	4
153	Assessing the disease burden of non-alcoholic fatty liver disease in the real world â€“ big data and big numbers. BMC Medicine, 2019, 17, 123.	2.3	4
154	Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis. JHEP Reports, 2020, 2, 100081.	2.6	4
155	Emerging Pharmacological Treatment in Nonalcoholic Steatohepatitis. Visceral Medicine, 2020, 36, 411-416.	0.5	4
156	TNF/TNF Receptors. , 2010, , 161-177.		4
157	Hepatocyte Bcl-3 protects from death-receptor mediated apoptosis and subsequent acute liver failure. Cell Death and Disease, 2022, 13, .	2.7	4
158	Long-term outcome in PSC patients receiving azathioprine: Does immunosuppression have a positive effect on survival?. Journal of Hepatology, 2020, 73, 1285-1287.	1.8	3
159	Urinary ethyl glucuronide (uEtG) as a marker for alcohol consumption in liver transplant candidates: a real-world cohort. Zeitschrift Fur Gastroenterologie, 2020, 58, 30-38.	0.2	3
160	Shortcut to death. Hepatology, 2009, 50, 2040-2043.	3.6	2
161	Show me your signalingâ€“ and Iâ€™ll tell you who you are. Journal of Hepatology, 2009, 51, 638-639.	1.8	2
162	Serological diagnosis of early HCC in NASH: A German multicenter study. Journal of Hepatology, 2018, 68, S421-S422.	1.8	2

#	Article	IF	Citations
163	Impact of non-selective ÃŸ-blockers on hepatic encephalopathy in patients with liver cirrhosis. European Journal of Internal Medicine, 2020, 82, 83-89.	1.0	2
164	Intestinal motility: a therapeutic target for NAFLD?. The Lancet Gastroenterology and Hepatology, 2020, 5, 957-958.	3.7	2
165	Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistanceâ€associated substitutions. Liver International, 2020, 40, 2660-2671.	1.9	2
166	Burden of illness of progressive familial intrahepatic cholestasis in the US, UK, France, and Germany: study rationale and protocol of the PICTURE study. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 247-253.	0.7	2
167	Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in nonâ€alcoholic fatty liver diseaseâ€"the role for nonâ€invasive testing. Alimentary Pharmacology and Therapeutics, 2021, 54, 214-215.	1.9	1
168	Letter: proton pump inhibitor use and bone fracture riskâ€"a mechanistic point of view. Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 673-673.	1.9	1
169	Refining imaging tools to detect advanced fibrosis: could liver surface nodularity address an unmet need in the NAFLD epidemic?. European Radiology, 2022, 32, 1757-1759.	2.3	1
170	Portal Vein Thrombosis Is Associated with an Increased Incidence of Depression and Anxiety Disorders. Journal of Clinical Medicine, 2021, 10, 5689.	1.0	1
171	CYP2E1 expression sensitizes hepatocytes to death from polyunsaturated fatty acids through ERK signaling. Gastroenterology, 2003, 124, A706-A707.	0.6	0
172	Predictors of the Metabolic Syndrome after Orthotopic Liver Transplantation Identified by a Retrospective Analysis. Transplantation, 2012, 94, 673.	0.5	0
173	Simple non-invasive fibrosis scores identify patients with non-alcoholic fatty liver disease who progress to advanced fibrosis/cirrhosis:evidence from a large cohort of patients with sequential liver biopsies. Journal of Hepatology, 2017, 66, S68-S69.	1.8	0
174	Editorial: stepwise risk stratification for both F3 and F4 in NAFLD patientsâ€"authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 1318-1319.	1.9	0
175	Prevalence, severity and patterns of clinicalpractice in outpatient visits for suspected NAFLD â€“ the German CONSTANS STUDY. Journal of Hepatology, 2018, 68, S830-S831.	1.8	0
176	Fatty liver disease â€“ A multifaceted disease with more than one name?. Liver International, 2020, 40, 2937-2938.	1.9	0
177	Obeticholic acid (OCA) improves non-invasive markers of fibrosis in patients with non-alcoholic steatohepatitis (NASH): a secondary analysis of the phase 3 Regenerate study. Digestive and Liver Disease, 2020, 52, e41-e42.	0.4	0
178	Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit. Gut, 2020, 69, 1377-1378.	6.1	0
179	Correspondence. Deutsches Ärzteblatt International, 2021, 118, 271-272.	0.6	0
180	Editorial: the polygenic risk of cirrhosis development. Alimentary Pharmacology and Therapeutics, 2021, 53, 849-850.	1.9	0

#	Article	IF	Citations
181	The unmet need of personalized HCC screeningâ€"Lessons learned from the Swedish nationwide registries. United European Gastroenterology Journal, 2022, 10, 447-448.	1.6	0